Here's Why Biogen Inc. (BIIB) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Feb 23, 2026

Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Investment Research • Feb 19, 2026

Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Biogen Inc. (BIIB) Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium Transcript

Seeking Alpha • Feb 13, 2026

Biogen Announces Board Chair Transition

Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair

GlobeNewsWire • Feb 11, 2026

Biogen Analysts Boost Their Forecasts After Upbeat Q4 Earnings

Biogen Inc. (NASDAQ: BIIB) on Friday reported better-than-expected fourth-quarter earnings.

Benzinga • Feb 9, 2026

Biogen FY25 Earnings: Stable EPS, Amid Pressure From The Multiple Sclerosis Franchise

Biogen (BIIB) is transitioning from a shrinking MS franchise to a portfolio anchored in rare disease and Alzheimer's therapies, driving improved mix quality. BIIB's 2025 growth products generated $3.3B, offsetting MS declines; non-GAAP EPS exceeded guidance at $15.28, reflecting strong cost discipline and operational execution. Despite a guided mid-single-digit revenue decline in 2026, BIIB maintains robust earnings power, with key catalysts, including Leqembi expansion and potential high-dose Spinraza approval.

Seeking Alpha • Feb 9, 2026

Biogen forecasts annual profit above estimates as Leqembi sales pick up

Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines and its Alzheimer's treatment Leqembi as older multiple sclerosis drugs battle pressure from cheaper versions.

Reuters • Feb 6, 2026

Why Biogen Stock Surged Almost 9% Higher on Friday

The biotech published its last set of financials for 2025. Its quarterly revenue and adjusted profitability declined, yet both still topped the consensus analyst estimates.

The Motley Fool • Feb 7, 2026

How One Drug Heavy-Lifted Biogen's Fourth-Quarter Beat

Biogen topped fourth-quarter expectations Friday, thanks to far better-than-expected sales of multiple sclerosis treatment Tysabri.

Investors Business Daily • Feb 6, 2026

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.

Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.

Barrons • Feb 6, 2026